Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts

Open access
Blattner, Mirjam, Lee, Daniel J., O'Reilly, Catherine, Park, Kyung, MacDonald, Theresa Y., Khani, Francesca, Turner, Kevin R., Chiu, Ya-Lin, Wild, Peter J., Dolgalev, Igor, Heguy, Adriana, Sboner, Andrea, Ramazangolu, Sinan, Hieronymus, Haley, Sawyers, Charles, Tewari, Ashutosh K., Moch, Holger, Yoon, Ghil Suk, Known, Yong Chul, Andrén, Ove, Fall, Katja, Demichelis, Francecsa, Mosquera, Juan Miguel, Robinson, Brian D., Barbieri, Christopher E., Rubin, Mark A.·2014·Neoplasia

Abstract

BACKGROUND: Recurrent mutations in the Speckle-Type POZ Protein (SPOP) gene occur in up to 15% of prostate cancers. However, the frequency and features of cancers with these mutations across different populations is unknown. OBJECTIVE: To investigate SPOP mutations across diverse cohorts and validate a series of assays employing high-resolution melting (HRM) analysis and Sanger sequencing for mutational analysis of formalin-fixed paraffin-embedded material. DESIGN SETTING AND PARTICIPANTS: 720 prostate cancer samples from six international cohorts spanning Caucasian, African American, and Asian patients, including both prostate-specific antigen-screened and unscreened populations, were screened for their SPOP mutation status. Status of SPOP was correlated to molecular features (ERG rearrangement, PTEN deletion, and CHD1 deletion) as well as clinical and pathologic features. RESULTS AND LIMITATIONS: Overall frequency of SPOP mutations was 8.1% (4.6% to 14.4%), SPOP mutation was inversely associated with ERG rearrangement (P<.01), and SPOP mutant (SPOPmut) cancers had higher rates of CHD1 deletions (P<.01). There were no significant differences in biochemical recurrence in SPOPmut cancers. Limitations of this study include missing mutational data due to sample quality and lack of power to identify a difference in clinical outcomes. CONCLUSION: SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds. There was no significant association between SPOP mutations with ethnicity, clinical, or pathologic parameters. Mutual exclusivity of SPOP mutation with ERG rearrangement as well as a high association with CHD1 deletion reinforces SPOP mutation as defining a distinct molecular subclass of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1593/neo.131704

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 159

Metadata

Authors
Blattner, M., Lee, D. J., O'Reilly, C., Park, K., MacDonald, T. Y., Khani, F., Turner, K. R., Chiu, Y.-L., Wild, P. J., Dolgalev, I., Heguy, A., Sboner, A., Ramazangolu, S., Hieronymus, H., Sawyers, C., Tewari, A. K., Moch, H., Yoon, G. S., Known, Y. C., Andrén, O., Fall, K., Demichelis, F., Mosquera, J. M., Robinson, B. D., Barbieri, C. E., & Rubin, M. A.
Venue
Neoplasia
Publisher
Elsevier BV
Published
2014-01
Volume
16
Issue
1
Pages
14-W10
ISSN
1476-5586 (ISSN-L)
OpenAlex
W1612799755
Cited by
159
References
4
FWCI
12.84
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. https://app.cochat.ai/papers/10.1593/neo.131704
The paper
Blattner, M., Lee, D. J., O'Reilly, C., Park, K., MacDonald, T. Y., Khani, F., Turner, K. R., Chiu, Y.-L., Wild, P. J., Dolgalev, I., Heguy, A., Sboner, A., Ramazangolu, S., Hieronymus, H., Sawyers, C., Tewari, A. K., Moch, H., Yoon, G. S., Known, Y. C., . . . Rubin, M. A. (2014). SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia. https://doi.org/10.1593/neo.131704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.